NCT00062283已完成2 期
A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients With MTAP-Deficient Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 12
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: This phase II trial is studying how well alanosine works in treating patients with soft tissue sarcoma, sarcoma of the bone, mesothelioma, non-small cell lung cancer, or pancreatic cancer.
详细描述
OBJECTIVES:
- Determine the response rates in patients with methylthioadenosine phosphorylase (MTAP)-deficient cancer when treated with alanosine.
- Determine the time to response and duration of response in patients treated with this drug.
- Determine the progression-free survival of patients treated with this drug.
- Determine the pharmacodynamic activity of this drug in these patients, based on special imaging to measure tumor adenosine triphosphate depletion.
- Determine the pharmacokinetic activity of this drug in these patients.
- Determine the safety and tolerability of this drug in these patients.
OUTLINE: This is a nonrandomized, open-label, multicenter study.
Patients receive alanosine IV continuously on days 1-5. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed at 28 days.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed malignancy of any of the following types:
- •Soft-tissue sarcoma
- •High grade
- •Chemotherapy naïve or progressive or metastatic after no more than 2 prior cytotoxic treatment regimens (not including adjuvant therapy)
- •Sarcoma of the bone (including osteosarcoma* and chondrosarcoma)
- •High grade
- •Progressive or recurrent after no more than 2 prior cytotoxic treatment regimens
- •No newly diagnosed or chemotherapy naïve disease NOTE: *Prior treatment with cisplatin and doxorubicin required
- •Mesothelioma
- •Unresectable
- •Chemotherapy naïve or progressive after no more than 1 prior cytotoxic chemotherapy regimen
- •Not amenable to curative treatment with surgery
- •Evidence of gross unresectability includes, but is not limited to, direct extension into the chest wall, mediastinal or hilar lymphadenopathy, pulmonary or cardiac function that is inadequate to tolerate resection, and sarcomatoid or mixed histology
- •Non-small cell lung cancer
- •Stage III with malignant pleural or pericardial effusion, stage IV, or progressive after no more than 2 prior cytotoxic chemotherapy regimens
- •No newly diagnosed or chemotherapy naïve disease
- •Pancreatic cancer
- •Stage IV adenocarcinoma after no more than 1 prior cytotoxic treatment regimen
- •No newly diagnosed or chemotherapy naïve disease
- •No Ewing's sarcoma of the soft tissue or bone
- •Documented absence of methylthioadenosine phosphorylase on fixed tumor specimens
- •Measurable disease
- •For all tumor types, at least 1 lesion measurable by MRI or CT scan
- •Chest x-ray allowed only for clearly defined lesions surrounded by aerated lung
- •Soft tissue component of bone disease considered measurable provided it can be measured by MRI or CT scan
- •Must be outside of a previously irradiated area
- •No uncontrolled CNS metastases of primary tumor under study
- •Patients with brain metastases are eligible only if the brain metastases have been treated with prior radiotherapy and/or surgery, are neurologically stable with no progressing symptoms, and are off steroids and anticonvulsants
- •PATIENT CHARACTERISTICS:
- •18 and over (13 and over for osteosarcoma only)
- •Performance status
- •Life expectancy
- •At least 3 months
- •Hematopoietic
- •Absolute granulocyte count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- •Alkaline phosphatase no greater than 2.5 times ULN
- •AST and ALT no greater than 2.5 times ULN (5 times ULN if liver metastases are present)
- •Creatinine no greater than 1.5 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective barrier contraception during and for 4 weeks after study treatment
- •No premalignant bony lesions (e.g., Paget's disease)
- •No other concurrent active malignancy except completely excised nonmelanoma skin cancer or carcinoma in situ of the cervix or bladder
- •No serious infection
- •No medical or psychiatric condition that would preclude the achievement of the study objectives
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- 另有 16 项未显示
排除标准
- 未提供
研究者
研究点 (12)
Loading locations...
相似试验
已完成
1 期
Alanosine in Treating Patients With Progressive or Recurrent Malignant GliomasBrain and Central Nervous System TumorsNCT00075894National Cancer Institute (NCI)18
撤回
2 期
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerLung CancerNCT00006374Case Comprehensive Cancer Center
Unknown
2 期
ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung CancerLung CancerNCT00021008Jonsson Comprehensive Cancer Center
已完成
2 期
Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue SarcomaSarcomaNCT00052390Memorial Sloan Kettering Cancer Center
已完成
2 期
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificDrug/Agent Toxicity by Tissue/OrganBreast CancerLung CancerOvarian CancerLymphomaNCT00003269Scripps Health20